Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy

Clinical Biochemistry

Volumn 43, Issue 16-17, 2010, Pages 1294-1299

  Nezami, Nariman ^a,b   Safa, Javid ^c   Eftekhar Sadat, Amir Taher ^c   Salari, Behzad ^a   Ghorashi, Sona ^b   Sakhaee, Khashayar ^d   Khosraviani, Khashayar ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Diabetes; HMG CoA reductase inhibitors; Lovastatin; Nephropathy; Osteoprotegerin; RANK ligand

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MEVINOLIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DIABETIC NEPHROPATHY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG WITHDRAWAL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN DETERMINATION; TREATMENT DURATION;

BLOOD GLUCOSE; DEMOGRAPHY; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FASTING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; LOVASTATIN; MALE; MIDDLE AGED; OSTEOPROTEGERIN;

EID: 77957573786     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.08.012     Document Type: Article

References (44)

1. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Lüthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
2. Schoppet M., Preissner K.T., Hofbauer L.C. RANK ligand and osteoprotegerin paracrine regulator of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002, 22:549-553.
3. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
4. Price P.A., June H.H., Buckley J.R., Williamson M.K. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001, 21:1610-1616.
5. Bennett B.J., Scatena M., Kirk E.A., Rattazzi M., Varon R.M., Averill M., et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 2006, 26:2117-2124.
6. Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002, 106:1192-1194.
7. Schoppet M., Sattler A.M., Schaefer J.R., Herzum M., Maisch B., Hofbauer L.C. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003, 88:1024-1028.
8. Abedin M., Omland T., Ueland T., Khera A., Aukrust P., Murphy S.A., et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007, 99:513-518.
9. Rhee E.J., Lee W.Y., Kim S.Y., Kim B.J., Sung K.C., Kim B.S., et al. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond) 2005, 108:237-243.
10. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109:2175-2180.
11. Omland T., Ueland T., Jansson A.M., Persson A., Karlsson T., Smith C., et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008, 51:627-633.
12. Van Campenhout A., Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009, 204:321-329.
13. Secchiero P., Corallini F., Pandolfi A., Consoli A., Candido R., Fabris B., et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 2006, 169:2236-2244.
14. Rasmussen L.M., Tarnow L., Hansen T.K., H.P.H., Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006, 154:75-81.
15. Anand D.V., Lahiri A., Lim E., Hopkins D., Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006, 47:1850-1857.
16. Knudsen S.T., Foss C.H., Poulsen P.L., Andersen N.H., Mogensen C.E., Rasmussen L.M. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003, 149:39-42.
17. Xiang G.D., Pu J.H., Zhao L.S., Sun H.L., Hou J., Yue L. Association between plasma osteoprotegerin concentrations and urinary albumin excretion in type 2 diabetes. Diabet Med 2009, 26:397-403.
18. Terekeci H.M., Senol M.G., Top C., Sahan B., Celik S., Sayan O., et al. Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy. Exp Clin Endocrinol Diab 2009, 117:119-123.
19. Ishiyama M., Suzuki E., Katsuda J., Murase H., Tajima Y., Horikawa Y., et al. Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients. Diabetes Res Clin Pract 2009, 85:189-196.
20. Akinci B., Demir T., Celtik A., Baris M., Yener S., Ozcan M.A., et al. Serum osteoprotegerin is associated with carotid intima media thickness in women with previous gestational diabetes. Diab Res Clin Pract 2008, 82:172-178.
21. Sadowitz B., Maier K.G., Gahtan V. Basic Science Review: Statin therapy-part I: the pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg 2010, 44:241-251.
22. Lipinski M.J., Abbate A., Fuster V., Vetrovec G.W. Drug insight: statins for nonischemic heart failure: evidence and potential mechanisms. Nat Clin Pract Cardiovasc Med 2007, 4:196-205.
23. van der Harst P., Voors A.A., van Gilst W.H., Böhm M., van Veldhuisen D.J. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 2006, 71:443-454.
24. Gadi R., Samaha F.F. Dyslipidemia in type 2 diabetes mellitus. Curr Diab Rep 2007, 7:228-234.
25. Jilma B., Dirnberger E., Löscher I., Rumplmayr A., Hildebrandt J., Eichler H.G., et al. Menstrual cycle-associated changes in blood levels of interleukin-6, alpha1 acid glycoprotein, and C-reactive protein. J Lab Clin Med 1997, 130:69-75.
26. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
27. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
28. Knudsen S.T., Jeppesen P., Poulsen P.L., Andersen N.H., Bek T., Schmitz O., et al. Plasma concentrations of osteoprotegerin during normo- and hyperglycaemic clamping. Scand J Clin Lab Invest 2007, 67:135-142.
29. Yaturu S., Rains J., Jain S.K. Relationship of elevated osteoprotegerin with insulin resistance, crp, and tnf-alpha levels in men with type 2 diabetes. Cytokine 2008, 44:168-171.
30. Shin J.Y., Shin Y.G., Chung C.H. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diab Care 2006, 29:1664-1666.
31. Vega D., Maalouf N.M., Sakhaee K. Clinical Review #: The role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007, 92:4514-4521.
32. Avignon A., Sultan A., Piot C., Elaerts S., Cristol J.P., Dupuy A.M. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diab Care 2005, 28:2176-2180.
33. Crisafulli A., Micari A., Altavilla D., Saporito F., Sardella A., Passaniti M., et al. Serum levels of osteoprotegerin and RANKL in patients with st elevation acute myocardial infarction. Clin Sci (Lond) 2005, 109:389-395.
34. Grundy S.M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988, 319:24-32.
35. Kempler P. Learning from large cardiovascular clinical trials: classical cardiovascular risk factors. Diab Res Clin Pract 2005, 68:S43-S47.
36. Celińska-Löwenhoff M., Löwenhoff T., Undas A., Gluszko P. Effects of hypolipemic drugs on the osteoprotegerin - sRANKL system in patients with coronary artery disease. Thromb Haemost 2007, 97:868-870.
37. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004, 95:1046-1057.
38. Nellemann B., Gormsen L.C., Dollerup J., Schmitz O., Mogensen C.E., Rasmussen L.M., et al. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diab Care 2007, 30:3122-3124.
39. Mori K., Jono S., Emoto M., Kawagishi T., Yasumoto H., Konishi T., et al. Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes. Angiology 2010, 61:86-91.
40. Kazama J.J., Shigematsu T., Yano K., Tsuda E., Miura M., Iwasaki Y., et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002, 39:525-532.
41. Nitta K., Akiba T., Uchida K., Kawashima A., Yumura W., Kabaya T., et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003, 42:303-309.
42. Morony S., Tintut Y., Zhang Z., Cattley R.C., Van G., Dwyer D., et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in LDLR(/) mice. Circulation 2008, 117:411-420.
43. Ueland T., Jemtland R., Godang K., Kjekshus J., Hognestad A., Omland T., et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004, 44:1970-1976.
44. Thunyakitpisal P.D., Chaisuparat R. Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (gelatinase b) in osteoblastic cells and ht1080 fibrosarcoma cells. J Pharmacol Sci 2004, 94:403-409.